[Pubmed] Treatment and clinical course of autoimmune myasthenia in Burkina Faso
Posté : 18 avr. 2025 12:00
Med Trop Sante Int. 2025 Feb 21;5(1):mtsi.v5i1.2025.646. doi: 10.48327/mtsi.v5i1.2025.646. eCollection 2025 Mar 31.
ABSTRACT
INTRODUCTION: In sub-Saharan Africa, autoimmune myasthenia gravis (AMG) is still poorly known and underdiagnosed (delayed diagnosis, poor availability and accessibility of proven effective diagnostic and therapeutic tools), resulting in a poor functional prognosis and high mortality. The aim of the present study was to evaluate the therapeutic and clinical course of AMG in Burkina Faso.
PATIENTS AND METHODS: This was a longitudinal, multicenter study conducted from March 2015 to April 2023. It included patients with clinical signs suggestive of myasthenia associated with the presence of serum anti-acetylcholine receptor (anti-RACh) antibodies and/or anti-muscle specific kinase (anti-MuSK) antibodies, and/or with the presence of a decrease >10% on electroneuromyography, and/or with a positive therapeutic test to oral anticholinesterase drugs. Data on treatment modalities and clinical evolution were analyzed using Epi InfoTM 7.2.5.0 software. Bivariate analysis with p-value calculation (
Source: https://pubmed.ncbi.nlm.nih.gov/4024857 ... t9+e462414